Numerous Independent Groups Presented Data that Supports Apabetalone's Potential Cardioprotective Benefits at European Society of Cardiology Congress 2024

Stock Information for Resverlogix Corp.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Resverlogix Corp.

Resverlogix Announces Voting Results from the 2025 Meeting of Shareholders
Resverlogix Announces Voting Results from the 2024 Meeting of Shareholders and Closing of Debenture Extension
Resverlogix Provides Update Regarding Two-Year Extension of Debenture and Elimination of Conversion Privileges
Resverlogix Announces Updated Annual and Special Meeting of Shareholders
Resverlogix Announces Two-Year Extension of Debenture and Elimination of Conversion Privileges
Resverlogix Announces Change to Its Board of Directors
Resverlogix Announces Publication of its 40th Scientific Journal Article on Apabetalone's Potential Therapeutic Benefits
Resverlogix Publishes on Apabetalone's Potential for the Treatment of FSHD, the Third Most Common Muscular Dystrophy

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.